Navigating an Increasingly Complex Treatment Paradigm in the Management of Multiple Sclerosis

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 1, 2020 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Biogen, Sanofi Genzyme, and Novartis Pharmaceuticals Corporation

Description:
Multiple Sclerosis (MS) is a chronic progressive disease and is the most common neurological cause of disability among young adults, with a prevalence of approximately 400,000 cases throughout the United States, and every week around 200 people are diagnosed with the disease. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. In many cases, MS may not be diagnosed for months to years after the onset of symptoms. Some strategies for diagnosis include a careful medical history, a neurologic exam and various tests, including a magnetic resonance imaging (MRI) and spinal fluid analysis. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Currently treatment is focused on disease-modifying agents, which helps lessen the frequency and severity of relapses, reduce lesions in the brain, and help slow or stop disability. Clinical data shows these agents have the ability to improve outcomes in both safety and efficacy as it relates to the management of patients with MS, especially in patients that haven't responded to previous treatments. Effective and timely treatment of relapsing MS can greatly improve the quality of life in MS patients.

Upon completion of this activity, participants will be able to:

  • Identify key indicators of multiple sclerosis (MS) to improve early diagnosis and initiation of treatment for MS

  • Analyze recent clinical data on the efficacy, safety, and dosing/administration of current and emerging MS therapies and their effect on staging and sequencing

  • Explore recent data related to available and investigational therapies for the treatment of progressive forms of MS

  • Employ treatment optimization approaches to balance costs with improved outcomes in MS management

  • Develop treatment strategies based on clinical phenotypes, goals, preferences, and potential biomarker findings in MS

  • Identify practices that managed care professionals can take to help improve outcomes, mitigate disease progression and ensure appropriate and timely access to disease-modifying therapies for MS


     

Faculty: Claire Riley, MD
Assistant Professor of Neurology
Columbia Irving Medical Center
Medical Director
Columbia University Multiple Sclerosis Center

Disclosure:

Dr. Riley has served on an advisory board for Genentech, Janssen, and Novartis. She serves as a consultant to EMD Serono and TG Therapeutics. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Biogen, Sanofi Genzyme, and Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue